Top Markets
#1 Islamic Coin Islamic Coin +151.47%
#2 DOVU DOVU +49.95%
#3 Black Phoenix Black Phoenix +34.49%
#4 Velvet Velvet +32.46%
#5 Akedo Akedo +15.63%
#6 DoubleZero DoubleZero +13.65%
#7 HOME HOME +12.67%
#8 Cross Cross +12.27%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.90%
#10 Cap Cap +10.33%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Classifica tra le azioni #33959
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Prezzo delle azioni
$17.15
Ultima sincronizzazione: 2026-08-03
Capitalizzazione di mercato
$6.51M
Variazione (1 giorno)
9.80%
Variazione (1 anno)
289.77%
Paese
US
Scambia Galera Therapeutics, Inc. (GRTX)

Categoria

Healthcare
Ricavi di Galera Therapeutics, Inc. (GRTX)
Ricavi nel Mar 2026 TTM: 0.00
Secondo gli ultimi rapporti finanziari di Galera Therapeutics, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0.00. Nel 2023, l'azienda ha registrato ricavi di 0.00 uguale a i ricavi dell'anno 2022, che erano pari a 0.00. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Galera Therapeutics, Inc. da 2017 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE